Income Statement Presentation 2023
Tecentriq: Further adjuvant read-outs in 2023
First positive read-out in adjuvant HCC; first PD-(L)1 with pivotal SC results filed
YoY CER growth
+24%
CHFM
1,100
1,000
900
+17%
800
+35%
700
+136%
600
500
400
300
200
100
0
Q4 19
Q4 20
Q4 21
Q4 22
US
Europe
International
Japan
Q4 update
• SC: EU and US filing (PDUFA date set for Sep 15th)
Lung franchise (NSCLC, SCLC)
•
EU: 1L SCLC with continued growth
• US: Continued strong launch in adjuvant NSCLC
Gl franchise (HCC)
•
US/EU/Japan: Further growth in 1L HCC
Roche
•
Ph III (IMbrave050) in adjuvant HCC met RFS primary endpoint;
OS immature
Outlook 2023
•
Ph III results in adjuvant SCCHN and TNBC expected; Ph III
(IMpower030) in periadjuvant NSCLC continues to 2024
•
⚫ Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab in 1L NSCLC
26
CER=Constant Exchange Rates; SC=subcutaneous; NSCLC-non-small cell lung cancer; HCC-hepatocellular cancer; RFS=recurrence-free survival; SCLC-small cell lung cancer; TNBC=triple-negative breast cancer;
SCCHN-squamous cell carcinoma of head and neck; PDUFA-prescription drug user fee act; OS-overall survivalView entire presentation